Prognostic Value of Serum Galectin-3 in Chronic Heart Failure: A Meta-Analysis

Abstract

ObjectiveTo evaluate the association between serum galectin-3 and all-cause death (ACD) and cardiovascular death (CVD) in patients with chronic heart failure (CHF).MethodsThe PubMed and Embase databases and Clinical Trials Registry (www.clinicaltrials.gov) were searched for studies with data on serum galectin-3 and ACD and CVD in CHF patients. The hazard ratios (HRs) of ACD and CVD were calculated and presented with 95% CIs. HRs were pooled using fixed effects or random effects models when appropriate. Sensitivity analysis, meta-regression and subgroup analysis were applied to find the origin of heterogeneity. Visual inspection of Begg's funnel plot and Egger's test were performed to assess the possibility publication bias.ResultsPooled data included the results from 6,440 patients from 12 studies in the meta-analysis. Higher serum galectin-3 was associated with a higher risk of ACD (HR, 1.38; 95% CI, 1.14–1.67) and CVD (HR, 1.13; 95% CI, 1.02–1.25) in CHF patients. In the subgroup analyses, higher serum galectin-3 was associated with an increased risk of ACD in all subgroups. The pooled HR of the shorter follow-up group (1.78; 95% CI, 1.50–2.11) was significantly higher than the pooled HR of the longer follow-up group (1.15; 95% CI, 1.05–1.25). Sensitivity analysis of eliminating one study in each turn indicated that Koukoui et al.'s study had the largest influence on the risk of all-cause death. All-cause death publication bias was not detected (Pr>|z| = 0.35 for Begg's test and P>|t| = 0.15 for Egger's test).ConclusionsSerum galectin-3 has prognostic value of both all-cause death and cardiovascular death in CHF. Serum galectin-3 could be useful for risk classification in patients with CHF.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=193399.

Macrophage-based therapeutic approaches for cardiovascular diseases

“…Multiple clinical studies have demonstrated that plasma levels of Gal-3 can effectively predict cardiovascular mortality [ 189 , 190 ]. In particular, a serum Gal-3 level exceeding 8.7 ng/mL has been identified as an independent predictor of heightened all-cause mortality risk in both MI and chronic heart failure patients [ 191 – 193 ]. The strong association between Gal-3 levels and HF severity highlights its potential as a prognostic marker and therapeutic target.…”

Effect of combined lipid-lowering therapy on atherosclerotic plaque vulnerability in patients with acute coronary syndrome (Combi-LLT ACS): randomized trial protocol

“…За дестабилизацию бляшек отвечает не только изменение их липидного состава, но и инфильтрация иммуновоспалительными клетками и деградация внеклеточного матрикса сосудистой стенки, а также активная воспалительная реакция и неоваскуляризация бляшки [1,2]. Немаловажна роль в этом процессе маркеров матриксного ремоделирования (матриксная металлопротеиназа-9 (MMP-9), тканевый ингибитор металлопротеиназы 1 типа (TIMP-1)), миокардиального фиброза и воспаления сосудистой стенки (галектин 3 (GAL-3), высокочувствительный С-реактивный белок (всч-СРБ), нейтрофильно-лимфоцитарное отношение (NLR), липокалин, ассоциированный с нейтрофильной желатиназой (NGAL)) [3][4][5][6][7][8][9][10][11][12][13][14]. В последние годы активно развивается направление кардиоваскулярной визуализации -внутрисосудистый ультразвук, магнитный резонанс высокого разрешения, позитронно-эмиссионная томография-компьютерная томография, оптическая когерентная томография (ОКТ), которые позволяют получать представление об характеристиках уязвимых бляшек in vivo [15].…”

“…Была предложена потенциальная роль GAL-3 как медиатора атеросклероза. Многие исследования показали, что GAL-3 способствует дифференцировке макрофагов, образованию пенистых клеток, эндотелиальной дисфункции и пролиферации, и миграции гладкомышечных клеток сосудов при атерогенезе [5,6].…”

“…Однако до настоящего времени отсутствуют достоверные данные о возможности использования указанных биомаркеров с целью долгосрочного конт роля за уязвимыми бляшками [3][4][5][6][7][8][9][10][11][12][13][14].…”

Correlations of sST2 and Gal-3 with Cardiothoracic Ratio in Patients with Chronic Kidney Disease

“…Under normal conditions, Gal-3 expression in the heart is minimal, but its production and release are elevated in the context of HF [26]. Further, a recent meta-analysis by Cheng Z. et al unveiled the prognostic significance of serum Gal-3 for both all-cause mortality and cardiovascular-related deaths among patients with chronic HF, highlighting its potential as a valuable tool for risk stratification in these patients [27]. Additionally, a study on the readmission rates of HF patients found that individuals with Gal-3 levels exceeding 17.8 ng/mL had a notably higher rate of rehospitalization.…”